Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis

Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $5.93 to $6.50
• 50-Day Range: $4.08 to $6.54
• 52-Week Range: $3.79 to $12.36
• Volume: 23.55 million shs
• Average Volume: 33.10 million shs
• Market Capitalization: $2.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Recursion Pharmaceuticals Stock Analysis - MarketRank™

Recursion Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat, and ranked 803rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Recursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Recursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($1.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Recursion Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Recursion Pharmaceuticals is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Recursion Pharmaceuticals has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.52% of the float of Recursion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Recursion Pharmaceuticals has recently decreased by 2.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Recursion Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Recursion Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

35.52% of the float of Recursion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Recursion Pharmaceuticals has recently decreased by 2.22%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.45

News Sentiment

Recursion Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Recursion Pharmaceuticals this week, compared to 10 articles on an average week.

Search Interest

78 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.

MarketBeat Follows

35 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 6% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Recursion Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.43% of the stock of Recursion Pharmaceuticals is held by insiders.

Percentage Held by Institutions

89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RXRX Stock Analysis - Frequently Asked Questions

How have RXRX shares performed this year?

Recursion Pharmaceuticals' stock was trading at $6.76 at the beginning of the year. Since then, RXRX stock has decreased by 4.0% and is now trading at $6.49.

How were Recursion Pharmaceuticals' earnings last quarter?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings data on Monday, May, 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.06. The business's revenue was up 7.2% compared to the same quarter last year.
Read the conference call transcript.

When did Recursion Pharmaceuticals IPO?

Recursion Pharmaceuticals (RXRX) raised $306 million in an IPO on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO.

Who are Recursion Pharmaceuticals' major shareholders?

Recursion Pharmaceuticals' top institutional shareholders include SteelPeak Wealth LLC (0.02%), Blair William & Co. IL (0.02%), KLP Kapitalforvaltning AS (0.02%) and Kieckhefer Group LLC (0.01%). Insiders that own company stock include Mubadala Investment Co Pjsc, Blake Borgeson, Michael Secora, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Shafique Virani, Terry-Ann Burrell and Zavain Dar.
View institutional ownership trends.

How do I buy shares of Recursion Pharmaceuticals?

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Recursion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/25/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RXRX
• CIK: 1601830
• Web: www.recursion.com
• Phone: 385-269-0203
• Fax: 801-821-2872
• Employees: 400
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Recursion Pharmaceuticals: $7.00
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +7.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$463.66 million
• Net Margins: -961.32%
• Pretax Margin: -962.17%
• Return on Equity: -74.70%
• Return on Assets: -54.02%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 4.11
• Quick Ratio: 4.11

Sales & Book Value

• Annual Sales: $58.84 million
• Price / Sales: 44.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 406,490,000
• Free Float: 372,227,000
• Market Cap: $2.64 billion
• Optionable: Optionable
• Beta: 0.91